background: Oocyte activation is a crucial step that comprises the release of the oocyte from meiotic arrest, pronuclear formation and subsequent embryo development. Oocytes are activated by repetitive increases in the intracellular concentration of free Ca 2+ , [Ca 2+ ] i oscillations, which are triggered during fertilization by the introduction of the sperm-specific phospholipase C zeta 1 (PLCZ1 results: A band of 68 kDa on recombinant protein was detected with both antibodies. Injection of recombinant hPLCZ1 induced [Ca 2+ ] i oscillations in a dose-dependent manner in both mouse and human oocytes. These oscillations, which closely resembled those initiated by the sperm upon fertilization, triggered activation and cleavage in oocytes of both species, although further development of the mice embryos was low. U73122, a PLC inhibitor, blocked the ability of hPLCZ1 to initiate oscillations. Microinjection of recombinant hPLCZ1 into ICSI-failed human oocytes rescued fertilization failure in five of eight attempts.
Introduction
Oocyte activation is a crucial step that initiates embryo development after the oocyte is released from meiotic arrest. Activation of mammalian oocytes is accomplished by the sperm, which induces the initiation of repeated elevations in the intracellular concentration of free Ca 2+ ([Ca 2+ ] i ), referred to as [Ca 2+ ] i oscillations (Miyazaki et al., 1986; Kline and Kline, 1992; Jones, 2007 (Swann, 1990; Wu et al., 1997; Stricker, 1999; Jones and Nixon, 2000; Rice et al., 2000; Kurokawa et al., 2004) . This protein factor was identified in mouse as sperm-specific phospholipase C zeta 1 (PLCZ1; Saunders et al., 2002; Kashir et al., 2010) , and was subsequently detected in monkey , human Rogers et al., 2004) , pig (Yoneda et al., 2006) , chicken (Coward et al., 2005) , rat (Ito et al., 2008) , horse (Bedford-Guaus et al., 2011) and fish (Coward et al., 2011) . Injection of recombinant protein or mRNA encoding PLCZ1 induced fertilization-like [Ca 2+ ] i oscillations , whereas immune depletion of PLCZ1 with a specific antibody from sperm extracts eliminated [Ca 2+ ] i oscillations . The finding that PLCZ1
is a physiologic agent of oocyte activation is further supported by a study on transgenic mice expressing short hairpin RNAs against PLCZ1, which led to reduced PLCZ1 protein expression. Fertilization by sperm of these transgenic mice caused [Ca 2+ ] i oscillations that terminated prematurely, litters were reduced in size and transgenic offspring were not generated (Knott et al., 2005) . A salient feature of PLCZ1 domain organization is that it lacks the pleckstrin homology domain, which is a typical domain in this family of proteins, and the EF hand motifs appear to be markedly sensitive to the Ca 2+ ion, which underlies its ability to initiate and support [Ca 2+ ] i oscillation (Kouchi et al., 2005; Nomikos et al., 2007) . ICSI, a commonly used assisted reproductive technique, has overcome many cases of male infertility (Palermo et al., 1992) . Despite the confirmed record of success with ICSI, this technique does not promise a positive outcome in every case (Maggiulli et al., 2010) . Inexplicably, ICSI yields fertilization rates ranging from 50 to 70% of oocytes in some cases, while complete fertilization failure is observed in about 3% of couples, and fertilization rates .50% are never reached in certain cases (Flaherty et al., 1995 (Flaherty et al., , 1998 . Recently, Yoon et al. (2008) showed that human sperm devoid of PLCZ1 fail to induce [Ca 2+ ] i oscillations, oocyte activation and pregnancy.
Further studies have revealed a specific maternally inherited point mutation in the PLCZ1 gene from some infertile men. Moreover, injection of mRNA encoding this mutation hinders the ability of the protein to induce [Ca 2+ ] i oscillations and oocyte activation, and may be the cause of infertility (Heytens et al., 2009; Kashir et al., 2012; Nomikos et al., 2011a) . Further evidence of the association between lack of Ca 2+ release at fertilization and infertility are the results demonstrating that ICSI couples with fertilization failure can overcome infertility if assisted oocyte activation (AOA) with pharmacological agents such as Ca 2+ ionophore (Borges et al., 2009b; Taylor et al., 2010; Check et al., 2010) , strontium chloride (Ma et al., 2005; Yanagida et al., 2006) , 7% anhydrous alcohol (Liu et al., 2011) or electric stimuli (Zhang et al., 1999; Versieren et al., 2010) is used after ICSI. The success of ICSI is also severely diminished in patients with globozoospermia, an infrequent disorder affecting only 0.1% of infertile men whose sperm display round-headed shapes that lack acrosomes. Several studies have reported successful oocyte activation with AOA after ICSI of patients exhibiting globozoospermia and poor ICSI success (Flaherty et al., 1995 (Flaherty et al., , 1998 Heytens et al., 2009) . Other clinical cases that might benefit from the use of AOA are non-obstructive azoospermic patients who need to rely on the injection of immature testicular spermatozoa such as round or elongated spermatids. In these cases, the injected testicular spermatids induce atypical [Ca 2+ ] i oscillations patterns, at least when tested in mouse oocytes, which likely fail to activate human oocytes during the ICSI procedure (Yazawa et al., 2007; Borges et al., 2009a) . Thus, artificial oocyte/oocyte activation procedures aid in the treatment of infertile patients who lack the ability to initiate the activating [Ca 2+ ] i signal (Murase et al., 2004; Chen et al., 2010; Nasr-Esfahani et al., 2010) . Unfortunately, the safety of the pharmacologic agents used to accomplish AOA has not been thoroughly tested and the [Ca 2+ ] i responses that they induce are far from physiological.
In this study, we have purified recombinant human PLCZ1 (hPLCZ1) protein and evaluated its [Ca 2+ ] i oscillation-inducing activity in mouse and human oocytes to further establish its potential clinical applicability, in lieu of non-biological agents for AOA.
Materials and Methods

Source of gametes
Human oocytes
This study was conducted on patients enrolled in the assisted reproduction program at the Fertility Center of CHA Gangnam Medical Center from December 2009 to June 2010. During this period, 50 oocytes were obtained from 19 of the consenting couples. The baseline characteristics of patients in this study are shown in Table I . The study was approved by the Institutional Review Board of CHA Gangnam Medical Center, and each woman gave informed written consent. Starting on the third day of the menstrual cycle, controlled ovarian hyperstimulation was carried out with recombinant FSH (rFSH) or rFSH/hMG. To prevent a premature LH surge, we used GnRH agonist (Lucrin; Abbott, Seoul, Korea) in the long protocol or the GnRH antagonist Cetrorelix (Cetrotide; Serono, Halle, Germany) after 5 -6 days of stimulation. Ovulation was triggered with 10 000 IU of hCG (Profasi; Serono) when at least two follicles were over 18 mm in diameter.
Transvaginal oocyte retrieval was carried out 34 -36 h after hCG administration. Only spare oocytes were donated for the study. Oocytes were selected from one cycle for each patient. After 2 -4 h incubation, cumulus masses of the oocytes were removed with a sharp needle and treated with 0.1% hyaluronidase in Dulbecco's phosphate-buffered saline (DPBS) (w/v) (Sigma, St. Louis, MO, USA) in preparation for the ICSI procedure. Only germinal vesicle breakdown (GVBD) oocytes without the first polar body (PB) were donated for this study. GBVD oocytes were transferred to the Infertility Research laboratory in Quinn's advantage medium with HEPES (Quinn's-HEPES; SAGE In Vitro Fertilization, Inc., Trumbull, CT, USA) containing 10% serum protein substitute (SPS; SAGE). Oocytes were cultured in fertilization medium (SAGE) supplemented with 10% SPS under mineral oil (SAGE) in an incubator at 378C in 5% CO 2 in air for 5 -7 h until they reached metaphase of meiosis with the first PB. Oocytes were observed every 1 h to confirm maturity and microinjected within 2 -3 h after extrusion of the first PB. To test the oocyte activating ability of recombinant hPLCZ1, in vitro matured oocytes were injected with recombinant hPLCZ1 and cultured for 24 h. Occytes that failed to fertilize after ICSI were tested in a similar way. The fertilization state of IVF/ICSI oocytes was observed 20 h post-IVF or ICSI.
Fertilization-failed oocytes were transferred to the research laboratory, and recombinant hPLCZ1 was microinjected within 2 h in an attempt to rescue fertilization. Activation of oocytes was confirmed by pronuclear formation at 20 h post-microinjection. To confirm ploidy, activated oocytes were subjected to fluorescence in situ hybridization (FISH).
Human sperm
Human sperm from fertility-proven patients were donated after IVF or ICSI with written consent.
Mouse oocytes
Five-to 6-week-old B6D2F1 or CD-1 mice (Samtako, Seoul, Korea) were superovulated via intraperitoneal injection of 5 IU pregnant mare serum gonadotrophin (PMSG; Sigma), followed by injection of 5 IU human chorionic gonadotrophin after 48 h (hCG; Intervet, Boxmeer, Netherlands). At 13.5 -14 h post-hCG, cumulus-enclosed oocytes were collected from oviducts, in Quinns-HEPES containing 10% SPS. Cumulus cells were removed from ovulated oocytes with 0.1% hyaluronidase (Sigma ] i -oscillatory activity, and those from Patient H and I tested in FISH experiments. Fertilization-failed oocytes after ICSI from Patients J to S were tested for 2-PN formation following recombinant hPLCZ1 microinjection. P represents pregnancy is diagnosed by a positive serum b-hCG test 12 days after ET and F represents failed pregnancy.
Oocyte activation by recombinant hPLCZ1
Human oocytes
To confirm human oocyte activation by injection of recombinant hPLCZ, the formation of a pronucleus (PN) was monitored after microinjection for 20 -24 h. FISH was performed to confirm the ploidy of oocytes activated with recombinant hPLCZ1. Activated zygotes were placed in a hypotonic solution (0.5% sodium citrate, Sigma) for 10 min and fixed in Carnoy's solution (methanol: acetic acid ¼ 3:1) for 10 min. Next, fixed cells were spread onto pre-cleaned glass slides, dehydrated and examined with by conventional FISH using Vysis LSI 13 and LSI 21 probes (Abbott Molecular Inc. Chicago, IL, USA). Hybridization was performed according to the manufacturer's instructions. The slides were washed and counterstained with 4
′ ,6-diamino-2-phenylindole dihydrochloride (DAPI). The signals were captured by the Axio Imager 2 fluorescent microscope (Carl Zeiss, Germany) with the Isis fluorescence and FISH imaging system version 5.3 (Metasystems, Germany).
Mouse oocytes
Microinjected oocytes were cultured for 5 days in KSOM. Activation and cleavage rates were assessed by second PB extrusion at 2 h, PN formation was assessed at 6 h post-microinjection, and further development was assessed every 24 h. As a control for the development study, ovulated mouse oocytes were activated with 10 mM Strontium Chloride (SrCl 2 ) in Ca 2+ -free CZB medium (Chatot et al., 1989; Ma et al., 2005) for 2 h and cultured in KSOM.
Cloning and in vitro transcription of hPLCZ1 RNA cDNA encoding full-length human phospholipase C, Zeta 1(hPLCZ1, GenBank accession No. NM_033123) was cloned from a cDNA library originated from human testis mRNA. cDNA was amplified with PCR using Pfu polymerase and following primers: forward, 5 ′ -TTAGCCTCCTG AACAGTCTTCTTCG-3 ′ and reverse, 5
′ -CATTTTGGCTGTTTTA TTGCGATGC-3 ′ . The amplified sequence was cloned into pGEM-T easy vector. The cDNA of hPLCZ1 was linearized with SalI and in vitro transcribed with T7 polymerase using the mMessage/mMachine capping kit (Ambion, Austin, TX, USA). Capped and poly (A)-tailed cRNAs were purified from the reaction mixture using the MEGA clear Kit (Ambion), eluted with 0.1% diethylpyrocarbonate-treated H 2 O, then put into aliquots at 0.5 mg/ ml, and where necessary, further diluted before microinjection.
Production of recombinant hPLCZ1 protein
Construction of pET-6His-hPLCZ1
The hPLCZ1 cDNA coding sequence was amplified from pGE MT-hPLCZ1 using the primers, 5
′ -CAAAAACTCCATATGCACCA CCACCACCACCA CATGGAAATGAGATGGTTTTTGTCAAAGATTC AG-3 ′ , incorporating an NdeI site and polyhistidine tag (6X Histidine) for purification, and 5 ′ -ACGTTCCTCGAGTTATC TGACGTACCAAAC ATAAACAAACAGTGA-3 ′ , including an XhoI site. The PCR product was gel-purified, digested with NdeI and XhoI, and the fragment (1845 bp) inserted into the corresponding restriction sites of pET22b (+). The new construct was designated pET-6His-hPLCZ1 and confirmed using DNA sequencing.
Transformation and protein expression
The pET-6His-hPLCZ1 construct was transformed into Escherichia coli DH5 [F-lacZDM15 hsdR17(r-m-) gyr A36]. Ampicillin-resistant colonies were screened by DNA isolation from 3 ml overnight cultures, followed by restriction mapping. Plasmid DNA was prepared and purified with the QIAprep Spin Miniprep kit (250) (QIAGEN, Hilden, Germany), and transformed into the expression host, E. coli BL21 (DE3) [F-omp T hsdS B (rB-mB) gal dcm (DE3)] (Stratagene, Agilent Technologies, Inc., Santa Clara, CA, USA). Cells were plated on Luria-Bertani (LB) plates. A single colony from a fresh plate was isolated and grown at 378C in 3 ml of LB broth containing 100 mg/ml ampicillin until the OD 600 reached 0.6. Cultures were further inoculated in 250 ml of LB with ampicillin, and grown at 378C on a shaking plate until OD 600 of 0.6. Protein was induced with 1 mM isopropyl-D-thio-galactopyranoside (IPTG) (Gibco w , Invitrogen Corporation, Carlsbad, CA, USA), and cultures were further grown at 208C for 12 h. Cells were centrifuged at 600g for 10 min at 48C. After three washes with 50 mM Tris -HCl (pH 8.0), cells were resuspended in 50 mM Tris-HCl, 0.5 M NaCl, 1 mM EDTA and 1 mM phenylmethylsulfonyl fluoride (PMSF, Sigma), followed by sonication. After centrifugation, the supernatant (soluble fraction) was mixed with 2X Laemmli sample buffer and boiled for 3 min for 4 -15% SDSpolyacrylamide gel electrophoresis (SDS -PAGE) (Laemmli, 1970) . Gels were stained with Coomassie Brilliant Blue R250 for visualization of protein (Sigma). E. coli cell extracts from DH5 [F-lacZDM15 hsdR17 (r-m-) gyr A36] cells transformed with the pET-6His-empty construct were used as the negative control in all experiments.
Immobilized metal affinity chromatography IDA Excellose resins (particle size: 125 -210 mm, Bioprogen, Korea) were poured onto a chromatographic column (Millipore, Billerica, MA, USA) saturated with nickel ions. A 50 mM solution of metal was applied to the column in the form of sulfate salt to remove unbound metal ions. The column was washed with distilled water, followed by 50 mM TrisHCl/0.5 M NaCl buffer (pH 8.0). All purification procedures were performed at room temperature in 1 mM EDTA containing 1 mM PMSF as the protease inhibitor. Sonicated cells were centrifuged at 16 000g, and the supernatant (soluble fraction) was applied to immobilized metal affinity chromatography (IMAC) (bed volume, 40 ml; 4 ml/min). For protein elution, the column was washed with 50 mM Tris -HCl/0.5 M NaCl buffer (pH 8.0) and a continuous imidazole gradient was applied by gradual mixing of 50 mM Tris-HCl/0.5 M NaCl buffer (pH 8.0) containing 500 mM imidazole with 50 mM Tris -HCl/0.5 M NaCl buffer (pH 8.0). The concentration of purified recombinant hPLCZ1 protein was determined with the Bradford assay (Bio-Rad, Hercules, CA, USA) or Qubit w 2.0 Fluorometer (Invitrogen), diluted in DPBS by to 1 mg/ml and stored at 2808C until use. Recombinant hPLCZ1 was further diluted in DPBS before microinjection. All four batches of recombinant hPLCZ1 were produced in the current study, and the activity of protein from each batch tested by microinjection into ovulated mouse oocytes. The [Ca 2+ ] i oscillation activity induced by the protein was compared with that with microinjection of cRNA (0.01 mg/ml). One batch was subsequently omitted from the experiment, since it did not show [Ca 2+ ] oscillation activity in the mouse ovulation oocyte test, and the remaining three batches were used.
Antibody preparation
Two antibodies were raised in rabbits (Rb 307) or rats (Rt 307) against a 17-mer peptide sequence ( 307 THERKGSDKRGDNQDKE 323 ) located within the linker domain of hPLCZ1. Rb307 was purified using protein A.
Western blotting of recombinant protein and sperm and immunostaining of sperm
For western blot, sperm were washed with three times in DPBS (Gibco w ), diluted to 50 000 per ml in 2× sample buffer and stored at 2208C. Recombinant hPLCZ1 protein was diluted in 2× sample buffer. Both sperm samples and recombinant hPLCZ1 were boiled for 3 min, loaded onto a 7.5% SDS gel, and transferred onto PVDF membranes via TransBlot w SD Semi-Dry Electrophoretic Transfer (Bio-Rad). Membranes were blocked in 5% non-fat dry milk in PBS (0.1% Tween-20) for 2 h and incubated overnight at 48C with the Rt307 antibody (1:500). After three washes, membranes were incubated for 1 h with a horseradish peroxidase-labeled secondary antibody (Bio-Rad). Immunoreactivity of bands was detected using chemiluminescence (Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA), and developed on Amersham Hyperfilm ECL (GE healthcare, Buckinghamshire, UK). The molecular weights of hPLCZ1 bands were analyzed using Kodak Image Station 440CF (Eastman Kodak Company, Rochester, NY, USA), based on protein markers (Bio-Rad).
Figures were prepared from the TIFF files using ImageJ software (NIH; http://rsb.info.nih.gov/ij/).
Negative controls and specific antibody blocking with the peptide were tested with pre-immune serum (PIS) or pre-incubation with the antigenic peptide of the antibody.
For immunostaining, human sperm were washed three times with DPBS and fixed in 4% paraformaldehyde for 15 min at 48C. Fixed sperm were loaded onto multi-well slide glass (Marienfeld-Superior, Am Wollerspfad, Germany), and permeabilized with 0.1% Triton-X 100 (Sigma) for 5 min on ice. Slides were blocked in 5% normal goat serum (NGS, Dako, Glostrup, Denmark) for 2 h at 48C, incubated with Rb 307 antibody (1:100) overnight in 5% NGS, and washed with DPBS. Following 1 h incubation at room temperature with Alexa Fluor 555-labeled goat anti-rabbit secondary antibody (1:200), sperm were counterstained with 5 mg/ml DAPI, mounted using VECTASHIELD w mounting medium (VECTOR Laboratories, Burlingame, CA, USA), and observed with a ×100 objective lens in oil immersion using an Axiovert 200 M microscope with a CCD camera controlled by AxioVision software 4.8.1 (Zeiss, Germany).
Negative controls and specific antibody blocking with the peptide were tested with PIS or pre-incubation with the antigenic peptide of the antibody.
Statistical analysis
Data were analyzed with the student's t-test using Graphpad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA) or x 2 test using EPISTAT (EPISTAT, Round Rock, TX, USA) and values are expressed as means + SEM. P-values of ,0.05 were considered statistically significant.
Results
Production of recombinant hPLCZ1 protein
Recombinant hPLCZ1 protein bearing an N-terminal His tag was purified as a major single band using IMAC technology, as evident from SDS-PAGE and staining with Coomassie Brilliant Blue R250 (Fig. 1A) . Collected fractions were subjected to SDS-PAGE and stained with Coomassie Brilliant Blue R250. A number of fractions displayed a major single band possibly corresponding to hPLCZ1-His ( Fig 1A, Lanes 2 -4) . These fractions were mixed and subjected to ultrafiltration (50 kDa, Amicon, Bedford, MA, USA). A lower band was assumed to represent an additional protein, non-purified E. coli protein or truncated hPLCZ1 (Fig. 1A , Lanes 5-8, Fig. 1B, Lane 6 ).
On the other hand, E. coli cell extracts of cells containing the pET-6His-empty construct did not display the major single band representing hPLCZ1-His (Fig. 1A , Lanes 9 and 10). Using specific antibodies against hPLCZ1, such as Rt307, a 70 kDa band was detected in sperm extracts from fertility-proven patients  Fig. 1B, Lanes 1, 2 and 7) , while a 68 kDa band was observed in lanes loaded with recombinant hPLCZ1 (Fig. 1B , Lanes 3-6 and 8). This 68 kDa band was additionally detected with the anti-His tag antibody in lanes with recombinant hPLCZ1 (Fig. 1B,  Lanes 10-12) . However, the recombinant hPLCZ1 band was not detected in extracts of E. coli cells transformed with the pET-6His-empty construct and treated with both anti-hPLCZ1 (Rt307) and anti-His tag antibodies (Fig. 1B, Lanes 9 and 15) . Moreover, native human sperm extracts incubated with anti-His tag antibody did not display any bands (Fig. 1B, Lanes 13 and 14) .The anti-hPLCZ1 antibody, Rb307, recognized the protein in the equatorial region of human sperm head from a fertile man (arrow in Fig. 1C,  PLCZ1 ). In contrast, PIS or Rb307 pre-incubated with antigenic peptide for 1 h failed to recognize the protein, although some reactivity remained on the sperm tail, which was considered non-specific Heytens et al., 2009 . As expected, the first rise had a longer duration, lasting for 5 -8 min, and it was followed by a second spike 10-12 min later, and thereafter the intervals between spikes seem to decrease progressively Rogers et al., 2004) . Injection of hPLCZ1 cRNA also induced oocyte activation, which was assessed by the rate of PN formation and cleavage to the 2-cell state and beyond ity, representing more than 10 spikes (score, +++) per 80 min, 10 showed 4 -9 spikes (score, ++), and only 2 showed 1-3 spikes (score, +) over the 80 min time-period. The average interval between spikes in the +++ group was 6-8 min. The majority of oocytes microinjected with 0.5 mg/ml recombinant hPLCZ1 only showed a few responses and were scored as + ( Fig. 2C and E ] i -concentration in five oocytes examined (0 mg/ml Fig. 2C ).
To confirm the phospholipase C activity of recombinant hPLCZ1, we employed U73122, a specific phospholipase C inhibitor (Fig. 2D) . Ovulated oocytes injected with 1 mg/ml recombinant hPLCZ1 were transferred to a Ca 2+ monitoring dish containing TL-HEPES supplemented with 20 mM U73122. For 7 out of 10 oocytes, only the first spike was displayed and there were no further oscillations, whereas 5 of 7 injected oocytes showed high [Ca 2+ ] i oscillatory activity in the presence of U73343, an inactive analog of U73122.
Next, we examined the oocyte activating ability of recombinant hPLCZ1 by injecting mouse ovulated oocytes with 0.5, 0.75 or 1 mg/ml of hPLCZ1 (Table III) . We observed second PB extrusion at 2 h post-microinjection to assess oocyte activation by recombinant hPLCZ1. Most of the oocytes extruding the second PB formed PN. Microinjection of 0.5 and 0.75 mg/ml of hPLCZ1 induced 46.8 + 13.0% and 46.0 + 7.5% PN formation, respectively, while oocytes injected with 1 mg/ml of hPLCZ1 showed an activation rate of 73.7 + 5.8% and visible formation of the second PB (Fig. 2F) . While Figure 1 SDS -PAGE and western blots of purified recombinant hPLCZ1. (A) SDS -PAGE of purified hPLCZ1. M, molecular marker; Lane 1, whole soluble fraction; Lanes 2 -4, three different fractions isolated using column chromatography; Lanes 5 -8, final purified hPLCZ1. Proteins were loaded onto each lane at concentrations of 0.6, 1.2, 2.4, 4.8 mg/lane, respectively. Lanes 9 and 10, 4.8 and 2.4 mg of whole cell extract from E. coli-transformed empty vector (pET-6His). (B) Western blot analysis of recombinant hPLCZ1. Lanes 1, 2, 7, 13 and 14, fertility-proven human sperm samples (500 K/lane); Lanes 3 and 10, 1.2 mg; Lane 4 and 11, 2.4 mg; Lane 5, 8 and 12, 4.8 mg; Lane 6, 9.6 mg of recombinant hPLCZ1, respectively. Lane 9 and 15, 2.4 mg of whole-cell extracts from E. coli transformed with empty vector (pET-6His). Lanes 1-9 were immunoblotted with the anti-hPLCZ1 antibody, Rt 307, and Lanes 10 -15 with anti-His tag. Bands of 70 kDa (Lanes 1, 2, 7) and 68 kDa (Lanes 3 -6, 8, 10 -12) were detected. Western blots of Lanes 2 -6 were run on the same gel. The presence of two vertical lines between lanes 2 and 3 indicates that lanes were cut and pasted from the same blot. The solid arrow represents the 68 kDa recombinant hPLCZ1, while the dotted arrow indicates 70 kDa hPLCZ1 in native sperm extracts. Arrow head indicates additional low-molecular protein. (C) Immunostaining of human sperm with the hPLCZ1 antibody, Rb 307. PLCZ1 localized to the equatorial region of human sperm head (white arrow). Negative controls, PIS and antigenic peptide of anti-hPLCZ1 did not display equatorial region staining (white arrowhead). Scale bar, 5mm.
this activation rate is markedly higher that that induced by lower concentrations of hPLCZ1 (P , 0.05), no significant differences in cleavage rates were observed from the 3-cell to 8-cell stages. Despite the high levels of activation, the rates of development to the morula stage were low. However, the oocytes injected with 0.1 mg/ml of hPLCZ1 showed similar rates of both activation and development to those activated with 10 mM SrCl 2 in Ca 2+ -free CZB medium for 2 h as a positive control (PN formation, 87% + 4.6; morula oscillations is similar to that following ICSI of human oocytes (Tesarik and Sousa, 1994) . Another group of oocytes did not display an initial, large spike, but rather showed low amplitude rises with high frequency (Fig. 3A, second graph) . Oocytes in a third group, 6 out of 28, showed very minor responses that terminated prematurely. We injected two human oocytes with DPBS as the negative control, prior to the recombinant hPLCZ1 microinjection experiment. These two human oocytes did not show any changes in [Ca 2+ ], similar to the pattern observed for the mouse negative control (Fig. 2C , 0 mg/ml of hPLCZ1). The [Ca 2+ ] i oscillatory activity of hPLCZ1 was affected by the source of oocytes, as oocytes from some patients showed distinctly higher oscillatory activity than the oocytes of other patients (Table IV) . We further analyzed whether recombinant hPLCZ1 was capable of activating human oocytes. Injections were performed in one in vitro matured metaphase II oocyte from one patient (Patient H in Table I ) and in two oocytes from a failed ICSI procedure (Patient I in Table I ). Following injection of 1 mg/ml of recombinant hPLCZ1, oocytes were cultured overnight in KSOM medium and assessed for PN formation. After 20 h, one oocyte from each patient formed a 1PN (Fig. 3B) , instead of two PN in normally fertilized oocytes. Ploidy of the oocyte in activation by recombinant hPLCZ1 injection was confirmed with FISH ( Fig. 3D and E) . One oocyte represented the haploid state with chromosome 13 (green spectrum) and chromosome 21(orange spectrum) in Fig. 3D , while the other oocyte failed to stain.
Finally, we investigated whether microinjection of recombinant hPLCZ1 improved 2PN in ICSI-failed oocytes. Superscripts within the same column represent significant differences (P , 0.05) using the student t-test. Oocytes were activated artificially in 10 mM SrCl 2 with Ca 2+ -free CZB for 2 h and cultured in KSOM.
hPLCZ1 formed 2PN, while one out of nine oocytes injected with DPBS formed 2PN (Table V, x 2 test, P , 0.05). We confirmed the diploid state of 2PN oocytes activated by recombinant hPLCZ1 by using FISH (Santos et al., 2003; Fig. 3E ).
Discussion
Sperm-initiated [Ca 2+ ] i oscillations represent the signaling event responsible for inducing oocyte activation and initiation of embryo development in mammals (Cuthbertson and Cobbold, 1985) . PLCZ1, a sperm-specific isoform of the PLC family of enzymes inducing IP 3 production, is thought to be responsible for stimulating Ca 2+ release during fertilization, but this is yet to be confirmed . For example, microinjection of PLCZ1 as cRNA or recombinant protein induces [Ca 2+ ] i oscillations and oocyte activation in mouse oocytes Kouchi et al., 2004) . Venus-tagged PLCZ1 cRNA microinjection into mouse oocytes results in PN formation, accumulation of PLCZ1 and cessation of oscillations, all of which are features of fertilization (Larman et al., 2004; Yoda et al., 2004; Kuroda et al., 2006) . Biochemical characterization of hPLCZ1 protein from sperm extracts indicated a mass of 70 kDa, estimated based on the NCBI Reference Sequence: NP_149114.2, as reported by Yoon et al. (2008) . Immunofluorescence studies additionally revealed localization to the post-acrosomal region of the sperm head, consistent with several reports (Fujimoto et al., 2004; Grasa et al., 2008; Yoon et al., 2008; Heytens et al., 2009) . The protein appears to be released from the sperm head following gamete fusion into the ooplasm where it reaches its substrate and triggers IP 3 production (Knott et al., 2003; Yoon and Fissore, 2007) . In this study, recombinant hPLCZ1 with the 6X His tag displayed a mass of 68 kDa, which is slightly lower than that of the native protein.
This discrepancy may be attributed to differences in post-translational modifications between the biological systems of E. coli (BL21) and human sperm (Butenas et al., 2010) . As an example, mCherry protein fused with 6X His-tagged recombinant hPLCZ1 produced in mammalian cells, such as human embryonic kidney cells (HEK293T), showed a mass of 74 kDa which is the expected size for expressed hPLCz protein . While the specific activity of our purified human recombinant PLCZ1 appeared lower, we managed to induce repetitive, fertilization-like [Ca 2+ ] i oscillations in mature mouse and human oocytes that caused activation in both species. In this regard, it is worth noting that recombinant hPLCZ1 induced normal fertilization-like [Ca 2+ ] i oscillation patterns at a minimal concentration of 1 mg/ml, which was the highest concentration we could obtain from the stock concentration. The amount of recombinant mouse PLCZ that triggered [Ca 2+ ] i oscillations in mouse oocytes has been shown to be in the range of 44-75 fg, and a single mouse sperm was estimated to contain 20 -50 fg of PLCZ . Several studies have suggested that human PLCZ is at least 10 times more potent in triggering [Ca 2+ ] i oscillations in mouse oocytes Rogers et al., 2004; Ito et al., 2008 ). In the current study, we injected about 5-10 pl of protein (1 mg/ml) into mouse oocytes, estimated as 5-10 pg of recombinant protein/ oocyte, which is almost 1000× more than that in a single mouse sperm. This suggests that the specific activity or purification levels of the active form of the protein are low . In fact, several lower molecular weight bands (,50 kDa) were observed for purified protein (Fig. 1A , arrowhead in Lane 8, and Fig. 1B , Lane 6), which may partly explain why the mouse oocytes activated with recombinant hPLCZ1 microinjection did not achieve embryonic development successfully. In addition, during production of this protein in E. coli, growth efficiency was extremely low at 308C. Accordingly, we cultured E. coli at 208C after IPTG induction to inhibit activation of the generated protein. We assumed that the active protein produces high concentrations of [Ca 2+ ] i, , which may be detrimental to E. coli growth.
We additionally observed a delayed response in [Ca 2+ ] i oscillations after microinjection of recombinant hPLCZ1. The first spike was not observed until about 20 min post-microinjection in mice oocytes. These results are suggestive of low concentrations of the active form of purified recombinant hPLCZ1 . On the other hand, the delayed response and requirement for high concentrations of protein may be attributed to post-translational modifications or interactions with other oocyte cytoplasmic proteins after fertilization (Cooney et al., 2010; Kashir et al., 2011) . There are a number of limitations on the usage of this recombinant hPLCZ protein, such as low activity of [Ca 2+ ] i oscillations and production from the E. coli expression system. However, these problems may be solved using other protein expression systems (such as the mammalian system) and optimized purification methods or enhanced understanding of the molecular characteristics of the functional units of this protein (Kouchi et al., 2005; Kurokawa et al., 2005; Nomikos et al., 2005 Nomikos et al., , 2011a Represents significant differences using x 2 test (P , 0.05).
scores of +, as shown in Fig 3A and Table IV . This may be attributed to the different ooplasmic maturation or condition attained by some of the oocytes matured in vitro from the GVBD stage oocytes after oocyte retrieval at 34-36 h post-hCG administration (De Vos et al., 1999; Balakier et al., 2004; Lacham-Kaplan and Trounson, 2008; Yan et al., 2011) . According to these results, recombinant hPLCZ1 may possibly be used to analyze oocyte quality or cytoplasmic maturity of ovulated oocytes. Interestingly, some human and mouse oocytes showed acceleration of [Ca 2+ ] i oscillations as the time after injection increased (Fig. 3A) . Ross et al. (2008) suggested that following injection of PLCZ1 cRNA, this phenomenon is caused by protein accumulation as a result of persistent translation. However, in the present study, we injected recombinant hPLCZ1 protein instead of hPLCZ1 cRNA (Ross et al., 2008) and propose that accelerated [Ca 2+ ] i oscillations are caused by sensitization of the ooplasm caused by persistent production of IP 3 . We cannot discount the possibility that with elapse of post-injection time, more active protein becomes available, which would occur if protein produced in bacteria acquires an inactive conformation that needs to be corrected before full activity is achieved. Thus, additional studies are required to establish the cause underlying this phenomenon. Several cases of male infertility appear associated with defects in the production or localization of PLCZ1. For example, maternally inherited point mutations in the catalytic domain of the protein have been detected in some infertile males (Heytens et al., 2009; Kashir et al., 2011 Kashir et al., , 2012 . Abnormal localization of PLCZ1 in sperm from wobbler mice has been shown to reduce the fertilizing ability of sperm (Heytens et al., 2010) . Furthermore, Yoon et al. (2008) demonstrated that human sperm from patients with failed ICSI were unable to induce [Ca 2+ ] i oscillations in mouse. Interestingly, in all these cases, artificial activation via ionophore or strontium treatment or microinjection of PLCZ cRNA into mouse oocytes overcame the activation deficit, and in some cases, infertility. However, cRNA or DNA microinjection into human oocytes is prohibited owing to safety reasons. To date, several clinical cases have demonstrated that AOA techniques, such as strontium activation (Yanagida et al., 2006) , ionomycin or ionophore treatment (Borges et al., 2009a) and electrical stimuli (Zhang et al., 1999) improve fertilization rates and restore fertility in many ICSI-failed patients. Interestingly, most patients displaying globozoospermia lack PLCZ1 and fail to activate oocytes after ICSI without AOA Heytens et al., 2009; Taylor et al., 2010) . AOA is also required after the use of testicular spermatids for ICSI, as given the late expression of PLCZ1 in spermatogenesis; these cells do not have a full complement of the protein (Borges et al., 2009a) . Thus, it appears that several cases of infertility can be safely overcome with AOA (Rybouchkin et al., 1997; Borges et al., 2009a) , although the safety of these procedures has not been thoroughly established. Results from the present study support the utility of highly purified hPLCZ1 as an alternative to AOA with pharmacological agents.
In conclusion, recombinant hPLCZ1 produced from E. coli can induce repeated [Ca 2+ ] i oscillations similar to those mediated by sperm, and activate mouse and human oocytes. Thus, microinjection of this recombinant protein may in the future provide an effective biological solution for artificial oocyte activation in cases of ICSI failure or male factor infertility.
